JAK2 and prostate carcinoma: Although most solid tumors do not have JAK2 mutations (63–65), more and more evidence shows that abnormal JAK2 signaling acts importantly in solid tumors (66) such as CRC (14, 67, 68), BC (69, 70), GC (71), lung cancer (72) and prostate cancer (73).